Literature DB >> 33441556

Establishing a clinical service to prevent psychosis: What, how and when? Systematic review.

Gonzalo Salazar de Pablo1,2, Andrés Estradé1,3, Marcello Cutroni4, Olivier Andlauer5,6, Paolo Fusar-Poli7,8,9,10.   

Abstract

The first rate-limiting step to successfully translate prevention of psychosis in to clinical practice is to establish specialised Clinical High Risk for Psychosis (CHR-P) services. This study systematises the knowledge regarding CHR-P services and provides guidelines for translational implementation. We conducted a PRISMA/MOOSE-compliant (PROSPERO-CRD42020163640) systematic review of Web of Science to identify studies until 4/05/2020 reporting on CHR-P service configuration, outreach strategy and referrals, service user characteristics, interventions, and outcomes. Fifty-six studies (1998-2020) were included, encompassing 51 distinct CHR-P services across 15 countries and a catchment area of 17,252,666 people. Most services (80.4%) consisted of integrated multidisciplinary teams taking care of CHR-P and other patients. Outreach encompassed active (up to 97.6%) or passive (up to 63.4%) approaches: referrals came mostly (90%) from healthcare agencies. CHR-P individuals were more frequently males (57.2%). Most (70.6%) services accepted individuals aged 12-35 years, typically assessed with the CAARMS/SIPS (83.7%). Baseline comorbid mental conditions were reported in two-third (69.5%) of cases, and unemployment in one third (36.6%). Most services provided up to 2-years (72.4%), of clinical monitoring (100%), psychoeducation (81.1%), psychosocial support (73%), family interventions (73%), individual (67.6%) and group (18.9%) psychotherapy, physical health interventions (37.8%), antipsychotics (87.1%), antidepressants (74.2%), anxiolytics (51.6%), and mood stabilisers (38.7%). Outcomes were more frequently ascertained clinically (93.0%) and included: persistence of symptoms/comorbidities (67.4%), transition to psychosis (53.5%), and functional status (48.8%). We provide ten practical recommendations for implementation of CHR-P services. Health service knowledge summarised by the current study will facilitate translational efforts for implementation of CHR-P services worldwide.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33441556      PMCID: PMC7807021          DOI: 10.1038/s41398-020-01165-x

Source DB:  PubMed          Journal:  Transl Psychiatry        ISSN: 2158-3188            Impact factor:   6.222


  119 in total

1.  Research and practice for ultra-high risk for psychosis: A national survey of early intervention in psychosis services in England.

Authors:  Helen J Stain; Lauren Mawn; Stephanie Common; Marie Pilton; Andrew Thompson
Journal:  Early Interv Psychiatry       Date:  2017-06-14       Impact factor: 2.732

2.  The Basel early-detection-of-psychosis (FEPSY)-study--design and preliminary results.

Authors:  A Riecher-Rössler; U Gschwandtner; J Aston; S Borgwardt; M Drewe; P Fuhr; M Pflüger; W Radü; Ch Schindler; R-D Stieglitz
Journal:  Acta Psychiatr Scand       Date:  2007-02       Impact factor: 6.392

3.  Identifying children and adolescents at ultra high risk of psychosis in Italian neuropsychiatry services: a feasibility study.

Authors:  Giulia Spada; S Molteni; C Pistone; M Chiappedi; P McGuire; P Fusar-Poli; U Balottin
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-04-30       Impact factor: 4.785

Review 4.  Early psychotic experiences: Interventions, problems and perspectives.

Authors:  S Dimitrakopoulos; C Kollias; N C Stefanis; V Kontaxakis
Journal:  Psychiatriki       Date:  2015 Jan-Mar

5.  Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study.

Authors:  Barnaby Nelson; Hok Pan Yuen; Stephen J Wood; Ashleigh Lin; Daniela Spiliotacopoulos; Annie Bruxner; Christina Broussard; Magenta Simmons; Debra L Foley; Warrick J Brewer; Shona M Francey; G Paul Amminger; Andrew Thompson; Patrick D McGorry; Alison R Yung
Journal:  JAMA Psychiatry       Date:  2013-08       Impact factor: 21.596

6.  Prenatal and perinatal risk and protective factors for psychosis: a systematic review and meta-analysis.

Authors:  Cathy Davies; Giulia Segre; Andrés Estradé; Joaquim Radua; Andrea De Micheli; Umberto Provenzani; Dominic Oliver; Gonzalo Salazar de Pablo; Valentina Ramella-Cravaro; Maria Besozzi; Paola Dazzan; Maddalena Miele; Gianluigi Caputo; Cecilia Spallarossa; Georgia Crossland; Athif Ilyas; Giulia Spada; Pierluigi Politi; Robin M Murray; Philip McGuire; Paolo Fusar-Poli
Journal:  Lancet Psychiatry       Date:  2020-03-24       Impact factor: 27.083

7.  Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis.

Authors:  Grazia Rutigliano; Lucia Valmaggia; Paola Landi; Marianna Frascarelli; Marco Cappucciati; Victoria Sear; Matteo Rocchetti; Andrea De Micheli; Ceri Jones; Erika Palombini; Philip McGuire; Paolo Fusar-Poli
Journal:  J Affect Disord       Date:  2016-05-31       Impact factor: 4.839

8.  Towards a Standard Psychometric Diagnostic Interview for Subjects at Ultra High Risk of Psychosis: CAARMS versus SIPS.

Authors:  P Fusar-Poli; M Cappucciati; G Rutigliano; T Y Lee; Q Beverly; I Bonoldi; J Lelli; S J Kaar; E Gago; M Rocchetti; R Patel; V Bhavsar; S Tognin; S Badger; M Calem; K Lim; J S Kwon; J Perez; P McGuire
Journal:  Psychiatry J       Date:  2016-05-30

9.  Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk and the Prediction of Psychosis: Second Replication in an Independent National Health Service Trust.

Authors:  Paolo Fusar-Poli; Nomi Werbeloff; Grazia Rutigliano; Dominic Oliver; Cathy Davies; Daniel Stahl; Philip McGuire; David Osborn
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

Review 10.  Psychosis Polyrisk Score (PPS) for the Detection of Individuals At-Risk and the Prediction of Their Outcomes.

Authors:  Dominic Oliver; Joaquim Radua; Abraham Reichenberg; Rudolf Uher; Paolo Fusar-Poli
Journal:  Front Psychiatry       Date:  2019-04-17       Impact factor: 4.157

View more
  11 in total

1.  Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis.

Authors:  Dominic Oliver; Maite Arribas; Joaquim Radua; Gonzalo Salazar de Pablo; Andrea De Micheli; Giulia Spada; Martina Maria Mensi; Magdalena Kotlicka-Antczak; Renato Borgatti; Marco Solmi; Jae Il Shin; Scott W Woods; Jean Addington; Philip McGuire; Paolo Fusar-Poli
Journal:  Mol Psychiatry       Date:  2022-06-03       Impact factor: 15.992

2.  The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics.

Authors:  Paolo Fusar-Poli; Andrés Estradé; Giovanni Stanghellini; Jemma Venables; Juliana Onwumere; Guilherme Messas; Lorenzo Gilardi; Barnaby Nelson; Vikram Patel; Ilaria Bonoldi; Massimiliano Aragona; Ana Cabrera; Joseba Rico; Arif Hoque; Jummy Otaiku; Nicholas Hunter; Melissa G Tamelini; Luca F Maschião; Mariana Cardoso Puchivailo; Valter L Piedade; Péter Kéri; Lily Kpodo; Charlene Sunkel; Jianan Bao; David Shiers; Elizabeth Kuipers; Celso Arango; Mario Maj
Journal:  World Psychiatry       Date:  2022-06       Impact factor: 79.683

3.  Clinical outcomes in brief psychotic episodes: a systematic review and meta-analysis.

Authors:  U Provenzani; G Salazar de Pablo; M Arribas; F Pillmann; P Fusar-Poli
Journal:  Epidemiol Psychiatr Sci       Date:  2021-11-04       Impact factor: 7.818

4.  What are the physical and mental health implications of duration of untreated psychosis?

Authors:  Gonzalo Salazar de Pablo; Daniel Guinart; Christoph U Correll
Journal:  Eur Psychiatry       Date:  2021-03-29       Impact factor: 5.361

5.  Public health primary prevention implemented by clinical high-risk services for psychosis.

Authors:  Andrés Estradé; Gonzalo Salazar de Pablo; Alice Zanotti; Scott Wood; Helen L Fisher; Paolo Fusar-Poli
Journal:  Transl Psychiatry       Date:  2022-01-28       Impact factor: 7.989

Review 6.  Prevalence of Individuals at Clinical High-Risk of Psychosis in the General Population and Clinical Samples: Systematic Review and Meta-Analysis.

Authors:  Gonzalo Salazar de Pablo; Scott W Woods; Georgia Drymonitou; Héctor de Diego; Paolo Fusar-Poli
Journal:  Brain Sci       Date:  2021-11-20

7.  New Electronic Health Records Screening Tools to Improve Detection of Emerging Psychosis.

Authors:  Paolo Fusar-Poli
Journal:  Front Psychiatry       Date:  2021-07-14       Impact factor: 4.157

8.  Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis.

Authors:  Gonzalo Salazar de Pablo; Livia Soardo; Anna Cabras; Joana Pereira; Simi Kaur; Filippo Besana; Vincenzo Arienti; Francesco Coronelli; Jae Il Shin; Marco Solmi; Natalia Petros; Andre F Carvalho; Philip McGuire; Paolo Fusar-Poli
Journal:  Epidemiol Psychiatr Sci       Date:  2022-01-19       Impact factor: 6.892

9.  Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis.

Authors:  Gonzalo Salazar de Pablo; Filippo Besana; Vincenzo Arienti; Ana Catalan; Julio Vaquerizo-Serrano; Anna Cabras; Joana Pereira; Livia Soardo; Francesco Coronelli; Simi Kaur; Josette da Silva; Dominic Oliver; Natalia Petros; Carmen Moreno; Ana Gonzalez-Pinto; Covadonga M Díaz-Caneja; Jae Il Shin; Pierluigi Politi; Marco Solmi; Renato Borgatti; Martina Maria Mensi; Celso Arango; Christoph U Correll; Philip McGuire; Paolo Fusar-Poli
Journal:  EClinicalMedicine       Date:  2021-06-16

Review 10.  Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies.

Authors:  Marco Solmi; Joaquim Radua; Miriam Olivola; Enrico Croce; Livia Soardo; Gonzalo Salazar de Pablo; Jae Il Shin; James B Kirkbride; Peter Jones; Jae Han Kim; Jong Yeob Kim; Andrè F Carvalho; Mary V Seeman; Christoph U Correll; Paolo Fusar-Poli
Journal:  Mol Psychiatry       Date:  2021-06-02       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.